The bill
PSA Screening for HIM Act
S. 297, 119th Congress — read as touching Health Insurance.
Sponsored by
Sen. Boozman, John [R-AR]
ID: B001236
Follow the money
The bill
S. 297, 119th Congress — read as touching Health Insurance.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
23 itemised contributions to this sponsor, pulled from FEC filings.
The alignment
This bill's text tracks the "Introduction" section, p. 503-505 of the Mandate for Leadership.
Track this bill's progress through the legislative process
Latest Action
Committee on Health, Education, Labor, and Pensions. Hearings held.
March 18, 2026
📍 Current Status
Next: The bill moves to the floor for full chamber debate and voting.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Another masterpiece of legislative theater, courtesy of Senators Boozman and Booker. The "PSA Screening for HIM Act" - because what's a more compelling title than one that sounds like a bad infomercial?
Let's dissect this bill, shall we? It's a regulatory Frankenstein, stitched together from spare parts of good intentions, lobbying dollars, and cynical politics.
**New regulations being created or modified:**
The bill amends the Public Health Service Act to require group health plans and insurance issuers to cover prostate cancer screenings without cost-sharing requirements for men aged 40 and above who are at high risk (African-American men and those with a family history). Because, of course, we need more unfunded mandates to drive up healthcare costs.
**Affected industries and sectors:**
Healthcare providers, insurers, and pharmaceutical companies will be impacted. Expect a windfall for screening manufacturers and urologists, as well as increased premiums for consumers.
**Compliance requirements and timelines:**
The amendments take effect... whenever the bill passes, because who needs a specific timeline when you're trying to curry favor with special interest groups? Insurers and healthcare providers will need to scramble to update their policies and procedures, all while navigating the Byzantine world of federal regulations.
**Enforcement mechanisms and penalties:**
The usual suspects: fines, lawsuits, and reputational damage for non-compliant entities. Because what's a regulatory bill without a healthy dose of fear-mongering?
**Economic and operational impacts:**
Increased costs for insurers, which will be passed on to consumers in the form of higher premiums. More screenings mean more false positives, unnecessary treatments, and iatrogenic harm (because we all know how well our healthcare system handles over-testing). And let's not forget the added administrative burden on already-strained healthcare providers.
In conclusion, this bill is a textbook example of regulatory capture, where special interest groups (in this case, urologists and screening manufacturers) manipulate lawmakers to create new revenue streams at the expense of consumers. It's a cynical exercise in feel-good politics, designed to generate headlines rather than meaningful reform.
As I always say: "Everybody lies." In this case, it's not just the politicians; it's also the voters who think they're getting something for nothing. Newsflash: you're not. You're just paying more for the privilege of being screened into oblivion.
Sen. Boozman, John [R-AR]
Congress 119 • 2024 Election Cycle
No PAC contributions found
No committee contributions found
This bill has 6 cosponsors. Below are their top campaign contributors.
ID: B001288
Top Contributors
10
ID: P000145
Top Contributors
10
ID: W000790
Top Contributors
10
ID: C000127
Top Contributors
10
ID: S001181
Top Contributors
10
ID: C001088
Top Contributors
10
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 55 nodes and 38 connections (39 secondary connections hidden)
Total contributions: $133,160
Showing top 19 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 1 helped, 1 harmed.
Section 3(a) amends the Public Health Service Act to require group health plans and health insurance issuers to provide coverage for prostate cancer screenings without cost-sharing, imposing a cost on insurers by eliminating patient cost-sharing for this service.
Section 3(a) requires coverage for prostate cancer screenings without cost-sharing, likely increasing utilization of screening services provided by hospitals and health systems, representing a benefit through increased demand.
This bill shows semantic similarity to the following sections of the Project 2025 policy document.
— 470 — Mandate for Leadership: The Conservative Promise from the subsidized market, giving the non-subsidized market regulatory relief from the costly ACA regulatory mandates.39 l Strengthen hospital price transparency. In 2020, CMS completed its rule to require hospitals to post the prices of common hospital procedures.40 Future updates of these rules should focus on including quality measures. Combined with the shared savings models and other consumer tools, these efforts could deliver considerable savings for consumers.41 Center for Consumer Information and Insurance Oversight (CCHO). CMS also plays an outsized role in overseeing the Obamacare exchanges, includ- ing managing Healthcare.gov, through the Center for Consumer Information and Insurance Oversight (CCIIO). While Obamacare limits plan options, CCIIO has been overly prescriptive in dictating what benefits and types of health plans may participate in the exchanges, thereby actually stifling market innovation and driv- ing up costs. Congress should build on the Trump Administration’s efforts to expand choices for small businesses and workers, both in and out of the exchanges, by codifying an expansion of association health plans, short-term health plans, and health reim- bursement arrangements (including individual coverage HRAs). CCIIO should also work with the Treasury Department and the Office of Management and Budget (OMB) to give consumers more flexibility with their health care dollars through expanded access to health savings accounts. EMERGENCY PREPAREDNESS l Expand the scope of practice of low-complexity and moderate- complexity clinical laboratories. During the COVID-19 pandemic, allowing laboratories greater regulatory flexibility regarding CLIA requirements increased access to testing. However, the need for regulatory flexibility is not limited to emergency situations. Ongoing innovations in medical care will continue to drive demand for clinical testing and new tests. One way that increasing demand for other medical services has been accommodated is by revising restrictions on scope of practice to enable providers to practice at the so-called top of their license. CMS should similarly revise CLIA rules regarding scope of practice for clinical laboratories and testing personnel.42 l Create CLIA-certification-equivalent pathways for non-clinical laboratories and researchers. The COVID-19 pandemic revealed that the U.S. needs to leverage the expertise of non-clinical laboratories and researchers in order to bolster clinical testing capacity. To accomplish this, — 471 — Department of Health and Human Services CMS should create pathways for granting non-clinical laboratories and their testing personnel CLIA certification equivalency. Non-clinical researchers already demonstrate their technical expertise through online training and certification programs. CMS should build on that existing framework so that those laboratories and personnel can similarly demonstrate their clinical testing capabilities.43 LIFE, CONSCIENCE, AND BODILY INTEGRITY l Prohibit abortion travel funding. Providing funding for abortions increases the number of abortions and violates the conscience and religious freedom rights of Americans who object to subsidizing the taking of life. The Hyde Amendment44 has long prohibited the use of HHS funds for elective abortions, but an August 2022 Biden executive order45 pressed the HHS Secretary to use his authority under Section 1115 demonstrations to waive certain provisions of the law in order to use taxpayer funds to achieve the Administration’s goal of helping women to travel out of state to obtain abortions. Moreover, the Department of Justice Office of Legal Counsel (DOJ OLC) issued a politicized legal opinion declaring, for the first time in the history of Hyde, that this action did not violate the Hyde Amendment and that Hyde applies only to the performance of the abortion itself in violation of the plainly broad language that Congress used. Two of the first actions of a pro-life Administration should be for HHS to withdraw the Medicaid guidance (and any Section 1115 waivers issued thereunder) and for DOJ OLC to withdraw and disavow its interpretation of the Hyde Amendment. l Prohibit Planned Parenthood from receiving Medicaid funds. During the 2020–2021 reporting period, Planned Parenthood performed more than 383,000 abortions.46 The national organization reported more than $133 million in excess revenue47 and more than $2.1 billion in net assets.48 During this same year, Planned Parenthood reports that its affiliates received more than $633 million in government funding and more than $579 million in private contributions.49 Planned Parenthood affiliates face accusations of waste, abuse and potential fraud with taxpayer dollars, failure to report the sexual abuse of minor girls, and allegations of profiting from the sale of organs from aborted babies. Policymakers should end taxpayer funding of Planned Parenthood and all other abortion providers and redirect funding to health centers that provide real health care for women. The bulk of federal funding for Planned
— 470 — Mandate for Leadership: The Conservative Promise from the subsidized market, giving the non-subsidized market regulatory relief from the costly ACA regulatory mandates.39 l Strengthen hospital price transparency. In 2020, CMS completed its rule to require hospitals to post the prices of common hospital procedures.40 Future updates of these rules should focus on including quality measures. Combined with the shared savings models and other consumer tools, these efforts could deliver considerable savings for consumers.41 Center for Consumer Information and Insurance Oversight (CCHO). CMS also plays an outsized role in overseeing the Obamacare exchanges, includ- ing managing Healthcare.gov, through the Center for Consumer Information and Insurance Oversight (CCIIO). While Obamacare limits plan options, CCIIO has been overly prescriptive in dictating what benefits and types of health plans may participate in the exchanges, thereby actually stifling market innovation and driv- ing up costs. Congress should build on the Trump Administration’s efforts to expand choices for small businesses and workers, both in and out of the exchanges, by codifying an expansion of association health plans, short-term health plans, and health reim- bursement arrangements (including individual coverage HRAs). CCIIO should also work with the Treasury Department and the Office of Management and Budget (OMB) to give consumers more flexibility with their health care dollars through expanded access to health savings accounts. EMERGENCY PREPAREDNESS l Expand the scope of practice of low-complexity and moderate- complexity clinical laboratories. During the COVID-19 pandemic, allowing laboratories greater regulatory flexibility regarding CLIA requirements increased access to testing. However, the need for regulatory flexibility is not limited to emergency situations. Ongoing innovations in medical care will continue to drive demand for clinical testing and new tests. One way that increasing demand for other medical services has been accommodated is by revising restrictions on scope of practice to enable providers to practice at the so-called top of their license. CMS should similarly revise CLIA rules regarding scope of practice for clinical laboratories and testing personnel.42 l Create CLIA-certification-equivalent pathways for non-clinical laboratories and researchers. The COVID-19 pandemic revealed that the U.S. needs to leverage the expertise of non-clinical laboratories and researchers in order to bolster clinical testing capacity. To accomplish this,
Policy matches are calculated using semantic similarity between bill summaries and Project 2025 policy text. A score of 60% or higher indicates meaningful thematic overlap. This does not imply direct causation or intent, but highlights areas where legislation aligns with Project 2025 policy objectives.